Search

Your search keyword '"Wu, Xue"' showing total 200 results
Start Over Author "Wu, Xue" Publication Year Range Last 10 years Publisher biomed central
200 results on '"Wu, Xue"'

11. Letter to the Editor: An ultra-sensitive assay using cell-free DNA fragmentomics for multi-cancer early detection

Author

Bao, Hua, Wang, Zheng, Ma, Xiaoji, Guo, Wei, Zhang, Xiangyu, Tang, Wanxiangfu, Chen, Xin, Wang, Xinyu, Chen, Yikuan, Mo, Shaobo, Liang, Naixin, Ma, Qianli, Wu, Shuyu, Xu, Xiuxiu, Chang, Shuang, Wei, Yulin, Zhang, Xian, Bao, Hairong, Liu, Rui, Yang, Shanshan, Jiang, Ya, Wu, Xue, Li, Yaqi, Zhang, Long, Tan, Fengwei, Xue, Qi, Liu, Fangqi, Cai, Sanjun, Gao, Shugeng, Peng, Junjie, Zhou, Jian, and Shao, Yang

Published
2022
Full Text
View/download PDF

14. Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer

Author

Wang, Siwei, Li, Ming, Zhang, Jingyuan, Xing, Peng, Wu, Min, Meng, Fancheng, Jiang, Feng, Wang, Jie, Bao, Hua, Huang, Jianfeng, Ren, Binhui, Yu, Mingfeng, Qiu, Ninglei, Li, Houhuai, Yuan, Fangliang, Zhang, Zhi, Jia, Hui, Lu, Xinxin, Zhang, Shuai, Wang, Xiaojun, Xu, Youtao, Xia, Wenjia, Liu, Tongyan, Xu, Weizhang, Xu, Xinyu, Sun, Mengting, Wu, Xue, Shao, Yang, Wang, Qianghu, Dai, Juncheng, Qiu, Mantang, Wang, Jinke, Zhang, Qin, Xu, Lin, Shen, Hongbing, and Yin, Rong

Published
2022
Full Text
View/download PDF

21. Mechanisms underlying neutrophils adhesion to triple-negative breast cancer cells via CD11b-ICAM1 in promoting breast cancer progression.

Author

Yang, Chenghui, Li, Lili, Ye, Zhiqiang, Zhang, Anqi, Bao, Yunjia, Wu, Xue, Ren, Guohong, Jiang, Chao, Wang, Ouchen, and Wang, Zhen

Subjects
TRIPLE-negative breast cancer, CELL adhesion, BREAST cancer, CANCER cells, NEUTROPHILS, CANCER invasiveness
Abstract

Background: Triple-negative breast cancer (TNBC) is recognized as the most aggressive and immunologically infiltrated subtype of breast cancer. A high circulating neutrophil-to-lymphocyte ratio (NLR) is strongly linked to a poor prognosis among patients with breast cancer, emphasizing the critical role of neutrophils. Although the involvement of neutrophils in tumor metastasis is well documented, their interactions with primary tumors and tumor cells are not yet fully understood. Methods: Clinical data were analyzed to investigate the role of neutrophils in breast cancer. In vivo mouse model and in vitro co-culture system were used for mechanism researches. Blocking experiments were further performed to identify therapeutic agents against TNBC. Results: TNBC cells secreted GM-CSF to sustain the survival of mature neutrophils and upregulated CD11b expression. Through CD11b, neutrophils specifically binded to ICAM1 on TNBC cells, facilitating adhesion. Transcriptomic sequencing combined with human and murine functional experiments revealed that neutrophils, through direct CD11b-ICAM1 interactions, activated the MAPK signaling pathway in TNBC cells, thereby enhancing tumor cell invasion and migration. Atorvastatin effectively inhibited ICAM1 expression in tumor cells, and tumor cells with ICAM1 knockout or treated with atorvastatin were unresponsive to neutrophil activation. The MAPK pathway and MMP9 expression were significantly inhibited in the tumor tissues of TNBC patients treated with atorvastatin. Conclusions: Targeting CD11b-ICAM1 with atorvastatin represented a potential clinical approach to reduce the malignant characteristics of TNBC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Multi-dimensional cell-free DNA-based liquid biopsy for sensitive early detection of gastric cancer.

Author

Yu, Pengfei, Chen, Ping, Wu, Min, Ding, Guangyu, Bao, Hua, Du, Yian, Xu, Zhiyuan, Yang, Litao, Fang, Jingquan, Huang, Xingmao, Lai, Qian, Wei, Jia, Yan, Junrong, Yang, Shanshan, He, Peng, Wu, Xue, Shao, Yang, Su, Dan, and Cheng, Xiangdong

Subjects
CIRCULATING tumor DNA, EARLY detection of cancer, WHOLE genome sequencing, STOMACH cancer, MONTE Carlo method, CELL-free DNA
Abstract

Background: Gastric cancer is the fifth most common cancer type. Most patients are diagnosed at advanced stages with poor prognosis. A non-invasive assay for the detection of early-stage gastric cancer is highly desirable for reducing associated mortality. Methods: We collected a prospective study cohort of 110 stage I–II gastric cancer patients and 139 non-cancer individuals. We performed whole-genome sequencing with plasma samples and profiled four types of cell-free DNA (cfDNA) characteristics, fragment size pattern, copy number variation, nucleosome coverage pattern, and single nucleotide substitution. With these differential profiles, we developed an ensemble model to detect gastric cancer signals. Further, we validated the assay in an in-house first validation cohort of 73 gastric cancer patients and 94 non-cancer individuals and an independent second validation cohort of 47 gastric cancer patients and 49 non-cancer individuals. Additionally, we evaluated the assay in a hypothetical 100,000 screening population by Monte Carlo simulation. Results: Our cfDNA-based assay could distinguish early-stage gastric cancer from non-cancer at an AUROC of 0.962 (95% CI: 0.942–0.982) in the study cohort, 0.972 (95% CI: 0.953–0.992) in the first validation cohort and 0.937 (95% CI: 0.890–0.983) in the second validation cohort. The model reached a specificity of 92.1% (128/139) and a sensitivity of 88.2% (97/110) in the study cohort. In the first validation cohort, 91.5% (86/94) of non-cancer individuals and 91.8% (67/73) of gastric cancer patients were correctly identified. In the second validation cohort, 89.8% (44/49) of non-cancer individuals and 87.2% (41/47) of gastric cancer patients were accurately classified. Conclusions: We introduced a liquid biopsy assay using multiple dimensions of cfDNA characteristics that could accurately identify early-stage gastric cancer from non-cancerous conditions. As a cost-effective non-invasive approach, it may provide population-wide benefits for the early detection of gastric cancer. Trial registration: This study was registered on ClinicalTrials.gov under the identifier NCT05269056 on March 7, 2022. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Correction: Reduction of NgR in perforant path decreases amyloid-β peptide production and ameliorates synaptic and cognitive deficits in APP/PS1 mice.

Author

Jiang, Rong, Wu, Xue-Fei, Wang, Bin, Guan, Rong-Xiao, Lv, Lang-Man, Li, Ai-Ping, Lei, Lei, Ma, Ye, Li, Na, Li, Qi-Fa, Ma, Quan-Hong, Zhao, Jie, and Li, Shao

Subjects
*PEPTIDES, *WESTERN immunoblotting, *MICE
Abstract

This document is a correction notice for an article titled "Reduction of NgR in perforant path decreases amyloid-β peptide production and ameliorates synaptic and cognitive deficits in APP/PS1 mice." The authors identified an error in Figure 6C(a) of the original article and have provided the corrected version. The corrected figure shows the Western blot and densitometry analysis of NgR and APP levels in APPswe/HEK293 cells. The original article has been updated with the corrected figure. The authors of the article are Rong Jiang, Xue-Fei Wu, Bin Wang, Rong-Xiao Guan, Lang-Man Lv, Ai-Ping Li, Lei Lei, Ye Ma, Na Li, Qi-Fa Li, Quan-Hong Ma, Jie Zhao, and Shao Li. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results